Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Current Considerations in the Treatment of Grade 3 Gliomas.
Jo J, Schiff D. Jo J, et al. Curr Treat Options Oncol. 2022 Sep;23(9):1219-1232. doi: 10.1007/s11864-022-01000-z. Epub 2022 Aug 1. Curr Treat Options Oncol. 2022. PMID: 35913658 Review.
In the 2021 WHO classification, these tumors are categorized into two types, grade 3 IDH mutant (IDHmt), 1p/19q codeleted oligodendroglioma and IDH mutant astrocytoma. ...In patients with IDHmt, codeleted oligodendrogliom …
In the 2021 WHO classification, these tumors are categorized into two types, grade 3 IDH mutant (IDHmt), 1p/19q …
Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline.
Halasz LM, Attia A, Bradfield L, Brat DJ, Kirkpatrick JP, Laack NN, Lalani N, Lebow ES, Liu AK, Niemeier HM, Palmer JD, Peters KB, Sheehan J, Thomas RP, Vora SA, Wahl DR, Weiss SE, Yeboa DN, Zhong J, Shih HA. Halasz LM, et al. Pract Radiat Oncol. 2022 Sep-Oct;12(5):370-386. doi: 10.1016/j.prro.2022.05.004. Epub 2022 May 31. Pract Radiat Oncol. 2022. PMID: 35902341
RESULTS: A strong recommendation for close surveillance alone was made for patients with oligodendroglioma, IDH-mutant, 1p/19q codeleted, WHO grade 2 after gross total resection without high-risk features. ...However, adjuvant RT was stro …
RESULTS: A strong recommendation for close surveillance alone was made for patients with oligodendroglioma, IDH-mutant, …
Comparison of diagnostic performance of radiologist- and AI-based assessments of T2-FLAIR mismatch sign and quantitative assessment using synthetic MRI in the differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
Kikuchi K, Togao O, Yamashita K, Momosaka D, Kikuchi Y, Kuga D, Yuhei S, Fujioka Y, Narutomi F, Obara M, Yoshimoto K, Ishigami K. Kikuchi K, et al. Neuroradiology. 2024 Mar;66(3):333-341. doi: 10.1007/s00234-024-03288-0. Epub 2024 Jan 15. Neuroradiology. 2024. PMID: 38224343 Free PMC article.
PURPOSE: This study aimed to compare assessments by radiologists, artificial intelligence (AI), and quantitative measurement using synthetic MRI (SyMRI) for differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, and IDH-mutant …
PURPOSE: This study aimed to compare assessments by radiologists, artificial intelligence (AI), and quantitative measurement using synthetic …
Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [(11)C]methionine PET.
Chen Q, Wang K, Ren X, Zhao X, Chen Q, Fan D, Zhang S, Li X, Ai L. Chen Q, et al. J Neurooncol. 2023 Dec;165(3):547-559. doi: 10.1007/s11060-023-04529-7. Epub 2023 Dec 14. J Neurooncol. 2023. PMID: 38095773
ROC analysis revealed TBR(max) had the best performance in differentiating TP from TRCs with a cut-off of 1.96 in IDH-mutant astrocytoma (AUC, 0.87; sensitivity, 93%; specificity 69%), 1.80 in IDH-mutant and 1p/19q-codeleted oli …
ROC analysis revealed TBR(max) had the best performance in differentiating TP from TRCs with a cut-off of 1.96 in IDH-mutant a …